Abstract: An apparatus for selectively detecting an anion in a medium and/or selectively measuring the concentration of an anion in a medium. The apparatus comprises at least one sensor and a conductive polymer film and is configured such that dielectric and/or electric property changes of the conductive polymer film can be detected by the sensor when the conductive polymer film is in hydraulic contact with the medium or after it has been in hydraulic contact with the medium. Methods of selectively detecting an anion in a medium and/or selectively determining a concentration of an anion in a medium are also provided.

Abstract: The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 ?, 5.14 ?, 4.84 ?, 4.55 ?, 4.34 ?, 4.07 ?, 3.51 ?, 3.48 ?, 3.25 ?, 3.19 ?, 3.15 ?, 3.07 ?, and 2.81 ?, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.

Abstract: A process for preparing compounds of formula I or a solvate or hydrate thereof, where R, R1, R2, R3 and R5 have the meanings as indicated in the specification. Such compounds are useful in the treatment of a number of conditions associated with substance P and neurokinin.

Abstract: The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 ?, 5.14 ?, 4.84 ?, 4.55 ?, 4.34 ?, 4.07 ?, 3.51 ?, 3.48 ?, 3.25 ?, 3.19 ?, 3.15 ?, 3.07 ?, and 2.81 ?, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.

Abstract: The present invention provides highly efficient methods for the preparation of {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-ethyl)-amine (I).

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.

Abstract: The invention provides compounds of formula (I) wherein R is as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals, for use in the treatment of any state associated with high levels of activeted PARP.

Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula 1

Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modification.

Abstract: The invention provides compounds of formula (I) wherein R is as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals, for use in the treatment of any state associated with high levels of activeted PARP.

Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula 1

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula their use and pharmaceutical preparations comprising this crystal modifications.

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula 1

Abstract: The invention relates on the one hand to a novel preparation of compounds of the formula (I) in which R1 is an aromatic or heteroaromatic radical, aromatic-aliphatic or heteroaromatic-aliphatic radical, a heterocyclic radical, a cycloaliphatic radical, a cycloaliphatic-aliphatic radical or an aliphatic radical, and on the other hand to novel compounds of the formula (I).

Abstract: The invention relates on the one hand to a novel preparation of compounds of the formula (I) ##STR1## in which R.sub.1 is an aromatic or heteroaromatic radical, aromatic-aliphatic or heteroaromatic-aliphatic radical, a heterocyclic radical, a cycloaliphatic radical, a cycloaliphatic-aliphatic radical or an aliphatic radical,and on the other hand to novel compounds of the formula (I).

Abstract: The invention relates to a novel process for producing 2-methoxybenzanthrones, starting with 1-aminoanthraquinones, which process is characterized in that, by application of a special reaction medium, namely a dimethylalkanephosphonate, which at the same time acts as a methylation agent in one of the reaction steps, the reaction is performed from beginning to end according to the principle of the single-vessel reaction, that is to say, without isolation of intermediates.The 2-methoxybenzanthrones obtained by this process are important intermediate products for vat dyes.

Abstract: The invention relates to a process for the preparation of azo dyes of the formula ##STR1## or mixtures thereof, in which Ar is a substituted or unsubstituted phenyl, naphthyl or aromatic heterocyclic radical and Y is a group of the formula --O--R, --S--R or ##STR2## in which R is a substituted or unsubstituted alkyl, aryl or heterocyclic radical and R.sub.1 and R.sub.2 independently of one another are hydrogen or a substituted or unsubstituted alkyl, aryl or heterocyclic radical, and the groups R.sub.1 and R.sub.2, together with the nitrogen atom to which they are bonded, can form a ring.The process comprises first coupling dimeric malonodinitrile with a diazo component and cyclizing the resulting intermediate with an alcohol, thioalcohol or amine.

Abstract: The invention relates to a process for the preparation of azo dyes of the formula ##STR1## or mixtures thereof, in which Ar is a substituted or unsubstituted phenyl, naphthyl or aromatic heterocyclic radical and Y is a group of the formula --O-R, --S-R or ##STR2## in which R is a substituted or unsubstituted alkyl, aryl or heterocyclic radical and R.sub.1 and R.sub.2 independently of one another are hydrogen or a substituted or unsubstituted alkyl, aryl or heterocyclic radical, and the groups R.sub.1 and R.sub.2, together with the nitrogen atom to which they are bonded, can form a ring.The process comprises first coupling dimeric malonodinitrile with a diazo component and cyclizing the resulting intermediate with an alcohol, thioalcohol or amine.

Abstract: A process for the production of 2-bromo-3-cyano-4,6-diaminopyridine by cyclization of malodinitrile with hydrogen bromide, which comprises reacting malodinitrile in lower aliphatic hydrogenated hydrocarbons with hydrogen bromide used in an excess of 1 to 10% above the stoichiometric amount at temperatures of -10.degree. C. to +30.degree. C.